Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Long-Term Investments (2022 - 2025)

Oramed Pharmaceuticals' Long-Term Investments history spans 4 years, with the latest figure at $37.6 million for Q4 2025.

  • For Q4 2025, Long-Term Investments changed N/A year-over-year to $37.6 million; the TTM value through Dec 2025 reached $37.6 million, changed N/A, while the annual FY2025 figure was $37.6 million, N/A changed from the prior year.
  • Long-Term Investments reached $37.6 million in Q4 2025 per ORMP's latest filing, up from $28.5 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $110.2 million in Q4 2023 to a low of $7000.0 in Q1 2023.
  • Average Long-Term Investments over 4 years is $14.6 million, with a median of $2.7 million recorded in 2022.
  • Peak YoY movement for Long-Term Investments: plummeted 99.64% in 2023, then surged 279100.0% in 2024.
  • A 4-year view of Long-Term Investments shows it stood at $2.7 million in 2022, then surged by 3981.04% to $110.2 million in 2023, then tumbled by 99.41% to $646000.0 in 2024, then surged by 5719.66% to $37.6 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Long-Term Investments are $37.6 million (Q4 2025), $28.5 million (Q3 2025), and $2.5 million (Q2 2025).